Verastem Reports Regulatory Strategy For Duvelisib NDA: 'Plans to Submit a Single NDA Requesting Full Approval of Duvelisib for the Treatment of Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma'